menu
    • menu
    [{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"AJU Pharm","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"ST-100","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Stuart Therapeutics \/ AJU Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Stuart Therapeutics \/ AJU Pharm"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"ST-113","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Stuart Therapeutics \/ Glaukos","highestDevelopmentStatusID":"5","companyTruncated":"Stuart Therapeutics \/ Glaukos"},{"orgOrder":0,"company":"Stuart Therapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vezocolmitide","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Stuart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stuart Therapeutics \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Stuart Therapeutics \/ Ora, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Stuart Therapeutics

    Menu

    Stuart Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stuart Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Stuart Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vezocolmitide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Ora, Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Stuart Therapeutics Announces First Patient, First Visit in Its Phase 3 Clinical Trial of Vezocolmitide for Dr...

                            Details : ST-100 (vezocolmitide) is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen. It is under phase 3 clinical development for the treatment of Dry Eye D...

                            Brand Name : ST-100

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 29, 2023

                            Lead Product(s) : Vezocolmitide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Ora, Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stuart Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Stuart Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ST-113

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Glaukos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos Corporation

                            Details : Under the agreement, Glaukos gains exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113, a synthesized collagen mimetic peptide, drug candidate for neuroprotection in glaucoma.

                            Brand Name : ST-113

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 18, 2023

                            Lead Product(s) : ST-113

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Glaukos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Stuart Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Stuart Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ST-100

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : AJU Pharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.

                            Details : ST-100 is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen.

                            Brand Name : ST-100

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : ST-100

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : AJU Pharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth